Morrissette, Jennifer J. D.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 862

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., et al. (2019) · Cancer Discovery

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 446

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers

Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L., Barrett, A., Kraya, A. A., Anastopoulos, I. N., Yu, S., et al. (2017) · Nature Communications

BRCA gene mutations in cancerPARP inhibition in cancer therapy

Cited by 296

Leukemia mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness

Pawar, A. S., Somers, P., Alex, A., Grana, J., Feist, V. K., George, S. S., Jalnapurkar, S. S., Antony, C., Verner, R., White-Brown, S. K., et al. (2025) · Genes & Development

Acute Myeloid Leukemia ResearchChromatin Remodeling and Cancer

Cited by 3